These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 18336625)

  • 1. The effects of methylprednisolone and mitoxantrone on CCL5-induced migration of lymphocytes in multiple sclerosis.
    Jalosinski M; Karolczak K; Mazurek A; Glabinski A
    Acta Neurol Scand; 2008 Aug; 118(2):120-5. PubMed ID: 18336625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCL5, CXCL10 and CXCL11 chemokines in patients with active and stable relapsing-remitting multiple sclerosis.
    Szczuciński A; Losy J
    Neuroimmunomodulation; 2011; 18(1):67-72. PubMed ID: 20720435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of multiple sclerosis relapse treatment on migration of effector T cells--Preliminary study.
    Jatczak-Pawlik I; Książek-Winiarek D; Wojkowska D; Jóźwiak K; Jastrzębski K; Pietruczuk M; Głąbiński A
    Neurol Neurochir Pol; 2016; 50(3):155-62. PubMed ID: 27154441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased CXCL8 (IL-8) expression in Multiple Sclerosis.
    Lund BT; Ashikian N; Ta HQ; Chakryan Y; Manoukian K; Groshen S; Gilmore W; Cheema GS; Stohl W; Burnett ME; Ko D; Kachuck NJ; Weiner LP
    J Neuroimmunol; 2004 Oct; 155(1-2):161-71. PubMed ID: 15342208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of multiple sclerosis with methylprednisolone and mitoxantrone modulates the expression of CXC chemokine receptors in PBMC.
    Bielecki B; Mazurek A; Wolinski P; Glabinski A
    J Clin Immunol; 2008 Mar; 28(2):122-30. PubMed ID: 17960472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucocorticoid Therapy of Multiple Sclerosis Patients Induces Anti-inflammatory Polarization and Increased Chemotaxis of Monocytes.
    Fischer HJ; Finck TLK; Pellkofer HL; Reichardt HM; Lühder F
    Front Immunol; 2019; 10():1200. PubMed ID: 31191554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: a possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis.
    Kopadze T; Dehmel T; Hartung HP; Stüve O; Kieseier BC
    Arch Neurol; 2006 Nov; 63(11):1572-8. PubMed ID: 17101825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody targeting of the CC chemokine ligand 5 results in diminished leukocyte infiltration into the central nervous system and reduced neurologic disease in a viral model of multiple sclerosis.
    Glass WG; Hickey MJ; Hardison JL; Liu MT; Manning JE; Lane TE
    J Immunol; 2004 Apr; 172(7):4018-25. PubMed ID: 15034013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of CCL5-driven mononuclear cell migration across the blood-brain barrier. Implications for therapeutically modulating neuroinflammation.
    Ubogu EE; Callahan MK; Tucky BH; Ransohoff RM
    J Neuroimmunol; 2006 Oct; 179(1-2):132-44. PubMed ID: 16857269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of high-dose methylprednisolone treatment on CCR5 expression on blood cells in MS exacerbation.
    Elovaara I; Kuusisto H; Paalavuo R; Särkijärvi S; Lehtimäki T; Huhtala H; Vilpo J
    Acta Neurol Scand; 2006 Mar; 113(3):163-6. PubMed ID: 16441245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Intercellular adhesion molecules and chemotaxic factors in the pathogenesis of multiple sclerosis].
    González-Amaro R; Sánchez-Madrid F
    Rev Neurol; 2002 Nov 16-30; 35(10):985-93. PubMed ID: 12436404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the treatment with methylprednisolone on the cerebrospinal fluid and serum levels of CCL2 and CXCL10 chemokines in patients with active multiple sclerosis.
    Moreira MA; Tilbery CP; Monteiro LP; Teixeira MM; Teixeira AL
    Acta Neurol Scand; 2006 Aug; 114(2):109-13. PubMed ID: 16867033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of methylprednisolone on the attention in patients with multiple sclerosis].
    Kułakowska A; Halicka D; Drozdowski W; Braszko JJ
    Pol Merkur Lekarski; 2006 Jan; 20(115):65-8. PubMed ID: 16617739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockade of chemokine signaling in patients with multiple sclerosis.
    Zipp F; Hartung HP; Hillert J; Schimrigk S; Trebst C; Stangel M; Infante-Duarte C; Jakobs P; Wolf C; Sandbrink R; Pohl C; Filippi M;
    Neurology; 2006 Nov; 67(10):1880-3. PubMed ID: 17130431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemokines, mononuclear cells and the nervous system: heaven (or hell) is in the details.
    Rebenko-Moll NM; Liu L; Cardona A; Ransohoff RM
    Curr Opin Immunol; 2006 Dec; 18(6):683-9. PubMed ID: 17010588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High dose of intravenously given glucocorticosteroids decrease IL-8 production by monocytes in multiple sclerosis patients treated during relapse.
    Mirowska-Guzel DM; Kurowska K; Skierski J; Koronkiewicz M; Wicha W; Kruszewska J; Czlonkowski A; Czlonkowska A
    J Neuroimmunol; 2006 Jul; 176(1-2):134-40. PubMed ID: 16723156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cognitive impact of mitoxantrone and methylprednisolone in multiple sclerosis: an open label study].
    Zéphir H; de Sèze J; Dujardin K; Dubois G; Cabaret M; Bouillaguet S; Ferriby D; Stojkovic T; Vermersch P
    Rev Neurol (Paris); 2008 Jan; 164(1):47-52. PubMed ID: 18342057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CCL5 and CCR5 genotypes modify clinical, radiological and pathological features of multiple sclerosis.
    van Veen T; Nielsen J; Berkhof J; Barkhof F; Kamphorst W; Bö L; Ravid R; Verweij CL; Huitinga I; Polman CH; Uitdehaag BM
    J Neuroimmunol; 2007 Oct; 190(1-2):157-64. PubMed ID: 17884183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitoxantrone does not restore the impaired suppressive function of natural regulatory T cells in patients suffering from multiple sclerosis. A longitudinal ex vivo and in vitro study.
    Putzki N; Kumar M; Kreuzfelder E; Grosse-Wilde H; Diener HC; Limmroth V
    Eur Neurol; 2009; 61(1):27-32. PubMed ID: 18948697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis.
    Cepok S; Schreiber H; Hoffmann S; Zhou D; Neuhaus O; von Geldern G; Hochgesand S; Nessler S; Rothhammer V; Lang M; Hartung HP; Hemmer B
    Arch Neurol; 2009 Oct; 66(10):1216-23. PubMed ID: 19667211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.